BioPharma Drive: Drug Pricing

AUGUST 8, 2023

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing 246

Marketing Pharmaceutical Companies Drugs Pharmaceuticals 246

BioPharma Drive: Drug Pricing

JULY 17, 2023

Meet the pharma marketer of the future, primed for personalization and powered by technology.

Marketing 246

Marketing 246

Drugs.com

JULY 19, 2024

FRIDAY, July 19, 2024 -- The U.S. Food and Drug Administration on Thursday authorized the sale of the country's best-selling e-cigarette.The agency's decision only applies to several tobacco-flavored versions of the reusable product, sold as Vuse.

Marketing 264

Marketing FDA Production Drugs 264

BioPharma Drive: Drug Pricing

AUGUST 14, 2023

Meet the pharma marketer of the future, primed for personalization and powered by technology.

Marketing 246

Marketing 246

BioPharma Drive: Drug Pricing

JANUARY 17, 2024

The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.

Marketing 309

Marketing 309

Drugs.com

FEBRUARY 21, 2024

WEDNESDAY, Feb. 21, 2024 -- A popular asthma inhaler was discontinued on Jan. 1, and the business move has left families scrambling to find a replacement for their kids.Flovent was one of the most commonly prescribed drugs for childhood asthma, but.

Marketing 293

Marketing Drugs 293

Drug Channels

NOVEMBER 15, 2024

The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies. TThey argue that unified datasets and the addition of AI-driven analytics tools can improve decision making throughout a drug’s life cycle.

Marketing 98

Marketing International Drugs 98

BioPharma Drive: Drug Pricing

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 253

Marketing Drugs 253

BioPharma Drive: Drug Pricing

SEPTEMBER 26, 2024

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

Trials 274

Trials Marketing Drugs 274

Drugs.com

JANUARY 17, 2025

Food and Drug Administration has authorized the marketing of 20 ZYN nicotine pouch products. FRIDAY, Jan. 17, 2025 -- Following an extensive scientific review, the U.S. Nicotine pouches -- small synthetic fiber pouches containing nicotine -- are.

FDA Approval 130

FDA Approval Marketing FDA Production 130

BioPharma Drive: Drug Pricing

MARCH 24, 2025

Understanding private sector breakthroughs, acquisitions and funding is critical in a volatile market.

Marketing 130

Marketing 130

BioPharma Drive: Drug Pricing

APRIL 4, 2024

In the wake of a major trial failure, the company is withdrawing Relyvrio and cutting costs with a restructuring that involves laying off 70% of its employees.

Marketing 177

Marketing Trials Drugs 177

BioPharma Drive: Drug Pricing

AUGUST 6, 2024

An advisory committee’s age group recommendations could curtail wider use for now, but executives at GSK, Pfizer and Moderna still see plenty of upside.

Marketing 170

Marketing Vaccine 170

Drug Patent Watch

FEBRUARY 27, 2025

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. But what can you do to protect your drug patent in global markets? Share your experiences and insights in the comments below!

Marketing 52

Marketing Drugs Regulations Pharmaceutical Companies 52

BioPharma Drive: Drug Pricing

NOVEMBER 1, 2023

Sales of GSK’s new RSV shot Arexvy were more than double what Pfizer reported for its rival product, suggesting substantial demand this fall.

Marketing 161

Marketing Vaccine Production 161

Drug Patent Watch

JANUARY 30, 2025

Maximizing Patent Protection: Strategies for Pharmaceutical Marketers As a pharmaceutical marketer, you know how crucial it is to protect your patented drug's market share. In this post, we'll explore effective strategies for maximizing patent protection and exclusivity, ensuring your product remains a leader in the market.

Marketing 59

Marketing Drugs Production Pharmaceuticals 59

BioPharma Drive: Drug Pricing

OCTOBER 31, 2023

The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID vaccine sales.

Vaccine 177

Vaccine Marketing Production 177

Drug Patent Watch

OCTOBER 21, 2024

The filing of drug patents in emerging markets is a critical aspect of this protection, as it ensures that companies can recoup their investments and… Source The pharmaceutical industry is a significant contributor to the global economy, with a substantial portion of its production costs incurred during the development stage.

Marketing 105

Marketing Drugs Pharmaceuticals Production 105

BioPharma Drive: Drug Pricing

FEBRUARY 9, 2024

Shortly after Kyverna priced one of the sector’s largest IPOs in recent years, Maag spoke with BioPharma Dive about what it takes to go public now.

Marketing 189

Marketing 189

Drug Patent Watch

SEPTEMBER 26, 2024

The generic drug market is a complex and dynamic environment where multiple factors influence the availability, quality, and pricing of generic drugs. Conducting an effective market analysis is crucial for pharmaceutical companies, policymakers, and healthcare professionals to understand the market dynamics and make informed decisions.

Marketing 105

Marketing Pharmaceutical Companies Drugs Pharmaceuticals 105

Drug Patent Watch

OCTOBER 10, 2024

China has emerged as a significant player in the global generic drug active pharmaceutical ingredient (API) market. This article will delve into the role of China in the global generic drug API market, exploring its market share… Source

Marketing 115

Marketing Pharmaceutical Companies Drugs Pharmaceuticals 115

Perficient: Drug Development

SEPTEMBER 17, 2024

This year, I’m particularly excited about how far we’ve advanced with Optimizely One in collaboration with Perficient, which is described as an operating system for marketing teams. Many organizations are shifting away from piecing together various products to build their marketing technology systems. Will you be at Opticon 2024?

Marketing 109

Marketing Production Government 109

BioPharma Drive: Drug Pricing

OCTOBER 29, 2024

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Vaccine 161

Vaccine Marketing 161

BioPharma Drive: Drug Pricing

JANUARY 13, 2025

How clinical services organizations are overcoming challenges in the APAC market.

Marketing 130

Marketing 130

Drug Patent Watch

SEPTEMBER 30, 2024

Patent expirations have a significant impact on the pharmaceutical industry, particularly on the generic drug market. When a drug’s patent expires, other manufacturers can produce and market generic versions of the drug, leading to increased competition and lower prices.

Marketing 105

Marketing Drugs Pharmaceuticals 105

BioPharma Drive: Drug Pricing

JULY 9, 2024

On Tuesday, regulators updated the public on their yearslong probe of PBM's business practices. The report faults PBMs for profiting at the expense of patients and independent pharmacists.

Marketing 141

Marketing Regulations Drugs 141

BioPharma Drive: Drug Pricing

NOVEMBER 5, 2024

Rallybio is headed into a mid-stage trial with enough cash to last it through 2026, but biotech's down market has made the company's journey difficult.

Marketing 130

Marketing Disease Trials 130

Perficient: Drug Development

OCTOBER 9, 2024

IDC Market Glance: Digital Business Professional Services, 3Q24 Perficient is thrilled to be included in the Technology Transformation Dominant consultancy category in the latest IDC Market Glance: Digital Business Professional Services report (doc #US51480824, September 2024).

Marketing 105

Marketing 105

BioPharma Drive: Drug Pricing

DECEMBER 19, 2023

A decision by European regulators to revoke approvals for five generic versions of Biogen's multiple sclerosis medicine helps cement the drug's monopoly there through early 2025.

Marketing 161

Marketing Regulations Drugs 161

Drugs.com

FEBRUARY 21, 2025

FRIDAY, Feb. 21, 2025 -- New York Attorney General Letitia James filed a major lawsuit yesterday, accusing 13 e-cigarette companies of illegally selling flavored vapes and targeting young kids through deceptive marketing.The 192-page complaint.

Marketing 147

Marketing 147

BioPharma Drive: Drug Pricing

MARCH 26, 2025

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

FDA 317

FDA Marketing Drugs 317

BioPharma Drive: Drug Pricing

MAY 22, 2024

Direct-to-consumer platforms can offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.

Marketing 152

Marketing 152

BioPharma Drive: Drug Pricing

SEPTEMBER 30, 2024

Clinical services organizations can help pharma with global drug development and clinical trial challenges.

Clinical Trials 130

Clinical Trials Marketing Drug Development Trials 130

BioPharma Drive: Drug Pricing

SEPTEMBER 12, 2024

The offerings by Bicara, Zenas and MBX give a glimpse into what industry insiders describe as a backlog of mature startups waiting for the right opportunity to test public markets.

Marketing 327

Marketing 327

BioPharma Drive: Drug Pricing

MAY 13, 2024

Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.

Therapies 325

Therapies Marketing Drugs 325

BioPharma Drive: Drug Pricing

MARCH 20, 2025

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a competitive and fast-changing market.

FDA Approval 274

FDA Approval Disease FDA Marketing 274

BioPharma Drive: Drug Pricing

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 321

Drugs Marketing 321